1. Home
  2. LXEO vs CMPS Comparison

LXEO vs CMPS Comparison

Compare LXEO & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$6.84

Market Cap

731.3M

Sector

N/A

ML Signal

HOLD

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$6.57

Market Cap

788.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXEO
CMPS
Founded
2017
2020
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
731.3M
788.9M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
LXEO
CMPS
Price
$6.84
$6.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
8
Target Price
$18.60
$27.14
AVG Volume (30 Days)
644.7K
4.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
75.08
0.86
EPS
N/A
N/A
Revenue
$654,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.45
$2.25
52 Week High
$10.99
$8.90

Technical Indicators

Market Signals
Indicator
LXEO
CMPS
Relative Strength Index (RSI) 44.15 44.15
Support Level $6.15 $5.95
Resistance Level $7.72 $7.02
Average True Range (ATR) 0.43 0.61
MACD 0.11 -0.10
Stochastic Oscillator 57.00 4.73

Price Performance

Historical Comparison
LXEO
CMPS

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Share on Social Networks: